%0 Journal Article
%T Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
%A Gun Min Kim
%A Hye Sook Han
%A In Hae Park
%A Jee Hyun Kim
%A Ji-Yeon Kim
%A Jin-Hee Ahn
%A Joohyuk Sohn
%A Keun Seok Lee
%A Ki Hyeong Lee
%A Korean Cancer Study Group
%A Kyung Hae Jung
%A Kyung-Hun Lee
%A Se Hyun Kim
%A Seock-Ah Im
%A Seri Park
%A Soo Jung Lee
%A Sung-Bae Kim
%A Tae-Yong Kim
%A Yee Soo Chae
%A Yeon Hee Park
%A Young-Hyuck Im
%J Archive of "Cancer Communications".
%D 2019
%R 10.1186/s40880-019-0375-7
%X The online version of this article (10.1186/s40880-019-0375-7) contains supplementary material, which is available to authorized users
%K Metastatic breast cancer
%K Eribulin
%K Paclitaxel
%K Neuropathy
%K Quality of life
%K Functional assessment of cancer therapy-taxane questionnaires
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540535/